Industry Pricing Tactics Are Driving Europe’s Cross-Country Backlash
Norwegian Minister Says Some Drug Prices Are 'Unethical'
A recent event in Brussels organized by the European Public Health Alliance found that cross-country initiatives on pricing and calls for more R&D and clinical trial transparency are gathering momentum in Europe, but there is still some way to go to address the imbalances in the system. The Pink Sheet spoke to EPHA's Yannis Natsis about the issues raised at the organization's fourth forum on medicines access.
You may also be interested in...
Varying levels of access to medicines across the EU are the result of market failures, high prices and pharmaceutical companies’ marketing strategies, says the Council of the EU, which will discuss these issues at the next meeting of European health ministers.
Civil society groups have welcomed a French parliamentary amendment that would require pharma firms to disclose any public R&D funding when negotiating drug prices with the health authorities. The pharmaceutical industry says the amendment does not take account of the realities of today's business model.
The European Medicines Agency may be forced to re-examine whether clinical trial data should be regarded as presumptively confidential under its access to documents policy.